New computer tool aims to boost cirrhosis care in hospitals

NCT ID NCT05967273

Recruiting now Knowledge-focused Sponsor: University of California, San Francisco Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests a computer program called CirrhosisRx that helps doctors follow national guidelines when treating hospitalized patients with cirrhosis. The tool organizes patient data and suggests appropriate orders. Researchers will compare care quality and patient outcomes between hospitals using the tool and those using usual care. About 2,100 adults with cirrhosis are being enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CirrhosisRx clinical decision support system (a computer tool that organizes patient data and suggests guideline-based orders)
What this could lead to: If it works, this tool could help doctors provide more consistent, guideline-based care for hospitalized cirrhosis patients, potentially reducing complications and deaths.
What could go wrong: This is a pragmatic trial testing a decision-support tool, not a new drug or cure. The tool may not change outcomes if doctors don't use it or if other factors limit its impact.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CIRRHOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cirrhosis of liver Fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CIRRHOSIS DECISION SUPPORT SYSTEMS, CLINICAL

Contacts and locations

Locations

University of California San Francisco Medical Center
RECRUITING

San Francisco, California, 94143, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.